Aliqopa OverviewCopanlisib (trade name Aliqopa /ælkop/ AL-ih-KOH-pah; codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies. Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells. For details see Mode of Action. Efficacy resulting in the approval of copanlisib was based on the subgroup of ...
Read more Aliqopa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Copanlisib
Recent Aliqopa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 60mg
- Powder: 60mg/vial
NDC Database Records for Aliqopa: (1 result)Sorted by National Drug Code
- 50419-385 Aliqopa 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Bayer Healthcare Pharmaceuticals Inc.